During the last session, Ocular Therapeutix Inc. (NASDAQ:OCUL)’s traded shares were 1.19 million, with the beta value of the company hitting 1.29. At the end of the trading day, the stock’s price was $6.24, reflecting an intraday loss of -6.31% or -$0.42. The 52-week high for the OCUL share is $7.32, that puts it down -17.31 from that peak though still a striking 58.81% gain since the share price plummeted to a 52-week low of $2.57. The company’s market capitalization is $476.99M, and the average intraday trading volume over the past 10 days was 1.14 million shares, and the average trade volume was 1.00 million shares over the past three months.
Ocular Therapeutix Inc. (OCUL) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. OCUL has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.28.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Ocular Therapeutix Inc. (NASDAQ:OCUL) trade information
Ocular Therapeutix Inc. (OCUL) registered a -6.31% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.31% in intraday trading to $6.24 this Thursday, 05/25/23, hitting a weekly high. The stock’s 5-day price performance is -2.04%, and it has moved by 3.83% in 30 days. Based on these gigs, the overall price performance for the year is 101.29%. The short interest in Ocular Therapeutix Inc. (NASDAQ:OCUL) is 5.53 million shares and it means that shorts have 5.03 day(s) to cover.
The consensus price target of analysts on Wall Street is $12.75, which implies an increase of 51.06% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $8.00 and $18.00 respectively. As a result, OCUL is trading at a discount of -188.46% off the target high and -28.21% off the low.
Ocular Therapeutix Inc. (OCUL) estimates and forecasts
Statistics show that Ocular Therapeutix Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Ocular Therapeutix Inc. (OCUL) shares have gone up 111.53% during the last six months, with a year-to-date growth rate less than the industry average at -28.87% against 13.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to shrink -12.00% this quarter and then jump 9.70% in the quarter after that. In the rating firms’ projections, revenue will increase 13.60% compared to the previous financial year.
Revenue for the current quarter is expected to be $14.36 million as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to $14.67 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $12.27 million and $14.27 million respectively. In this case, analysts expect current quarter sales to grow by 17.10% and then jump by 2.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 15.90%. While earnings are projected to return -977.30% in 2023.
Ocular Therapeutix Inc. is due to release its next quarterly earnings between August 07 and August 11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Ocular Therapeutix Inc. (NASDAQ:OCUL)’s Major holders
Ocular Therapeutix Inc. insiders own 1.15% of total outstanding shares while institutional holders control 52.10%, with the float percentage being 52.70%. Summer Road LLC is the largest shareholder of the company, while 160 institutions own stock in it. As of Mar 30, 2023, the company held over 6.12 million shares (or 7.90% of all shares), a total value of $32.26 million in shares.
The next largest institutional holding, with 6.11 million shares, is of Opaleye Management Inc.’s that is approximately 7.88% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $32.18 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ocular Therapeutix Inc. (OCUL) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.31 million shares. This amounts to just over 2.98 percent of the company’s overall shares, with a $6.48 million market value. The same data shows that the other fund manager holds slightly less at 1.71 million, or about 2.20% of the stock, which is worth about $10.3 million.